Andrew Webb Is Executive Search Leader
Our pharmaceutical pipeline covers 4 core areas; Respiratory Diseases, Infectious Disease / HIV, Immuno-inflammation and Oncology. We currently have around 40 new molecules, vaccines and biologicals in clinical development of which approximately 80% have the potential to be 1st in class with novel mechanisms of action. The depth and breadth of our pipeline marks a new chapter in R&D productivity; we have the potential to file up 20 assets prior to 2020 and a further 20 additional products between 2020 and 2025.